---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Access and distribution"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Access and distribution. Topics: Commercial preparation for a United States launch; Manufacturing, packaging, and distribution; Expanded access program in the United States (NCT07759141); Continued investigational access through the RAPIDe-2 open-label extension. 4 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/access-and-distribution"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Commercial preparation for a United States launch

> “Additionally, our team is preparing for our potential first commercial launch and is well on its way to building an experienced commercial team.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

> “In parallel to our recent regulatory successes, our ongoing pre-commercial activities are designed to support a timely, successful U.S. launch,”

Source: [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm)

> “With the build out of our commercial infrastructure already underway, Pharvaris is poised for a successful launch of deucrictibant IR, if approved.”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

> “We intend to develop a fully integrated sales and marketing organization ahead of marketing approval for deucrictibant IR or deucrictibant XR.”
> “If any of our product candidates receive marketing approval, we intend to market, sell and distribute them using our own commercial infrastructure.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.11-2"></a>

### Manufacturing, packaging, and distribution

> “We currently have two CDMOs for the production of deucrictibant active pharmaceutical ingredient (API).”
> “We also partner with a leading CDMO for the manufacturing of the on-demand treatment product, deucrictibant IR capsules.”
> “We partnered with a further Commercial Packaging Organization (CPO) with a global footprint for the packaging and labeling of commercial finished drug product.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.11-3"></a>

### Expanded access program in the United States (NCT07759141)

> “Expanded Access Program (EAP) for deucrictibant IR for the on-demand treatment of HAE attacks opened in the U.S.”
> “The U.S. EAP for deucrictibant IR is available to people in U.S. living with HAE meeting eligibility requirements.”

Source: [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm)

> “An expanded access program (EAP) (NCT07759141) for deucrictibant IR for the on-demand treatment of HAE attacks is also available to people in U.S. meeting eligibility requirements.”

Source: [Pharvaris RAPIDe-3 Lancet publication press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/phase-3-study-results-highlighting-deucrictibants-rapid-and)

> “This is an expanded access program (EAP) designed to allow access to deucrictibant immediate-release (IR) capsule for eligible participants with hereditary angioedema (HAE) in the United States (US) and US territories who lack satisfactory alternative treatment options for on-demand treatment of HAE attacks, as determined by their treating physician.”
> “The program will continue beyond the commercial availability of deucrictibant IR, upon regulatory approval, for up to approximately 6 months to ensure continuity of treatment for participants for whom ongoing therapy is considered appropriate.”
> “Male or female, aged ≥12 to ≤75 years at the time of providing written informed consent/assent.”
> “Residence in the US or US territories.”

Source: [ClinicalTrials.gov NCT07759141](https://clinicaltrials.gov/study/NCT07759141)

<a id="topic-2.1.2.11-4"></a>

### Continued investigational access through the RAPIDe-2 open-label extension

> “Part B is open-label treatment and includes participants rolling over from Part A, participants from Study PHA022121-C201 who did not participate in Part A, participants aged 12 years and older with HAE type I, type II, or HAE-nC1INH rolling over from Study PHA022121-C306, and deucrictibant treatment naïve adult participants with HAE-nC1INH who elect to participate in this extension study and meet the eligibility requirements.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-2.1.2.11-5"></a>

### Specialty pharmacy or limited distribution arrangements

No evidence found.

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
